Trastuzumab Deruxtecan

• Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patie… Recruiting
  2023-506662-31-00 Phase II 1 country Fondazione GONO G.I.
• A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer Recruiting
  2022-501504-95-00 Phase II 3 countries Karolinska University Hospital
• Window-of-opportunity umbrella platform trial of short-course pre-operative targeted treatments in patients with molecularly selected and re… Recruiting
  2022-501308-90-00 Phase II 1 country Fondazione GONO G.I.
• Study of AZD9574 as monotherapy and in combination with anti-cancer agents in patients with advanced solid malignancies Recruiting
  2023-504984-17-00 Phase I (FiH) 2 countries AstraZeneca AB
• A study of Trastuzumab Deruxtecan to assess its safety, tolerability, immune response, and inhibition of tumor activity when given alone or … Recruiting
  2023-504888-16-00 Phase I/II 5 countries AstraZeneca AB
• Master protocol of novel agents or combinations as perioperative treatment in participants with locally advanced resectable gastroesophagea… Ended
  2024-516909-23-00 Phase II 2 countries AstraZeneca AB
• A Multicenter, Open-Label, Single-Arm, Phase II Trial Exploring the Maintenance of Trastuzumab and Pertuzumab Following Trastuzumab Deruxtec… Ended
  2023-507306-13-00 Phase II 4 countries Medica Scientia Innovation Research S.L.
• Phase II Study of Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-Low Breast Cancer Patients Presenting with Newly Diagnosed or Progressing… Ended
  2023-506702-39-00 Phase II 2 countries Medica Scientia Innovation Research S.L.
• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+… Ended
  2024-514458-61-01 Phase II 1 country WSG Westdeutsche Studiengruppe GmbH
• Trastuzumab Deruxtecan (T-DXd): Tailoring Treatment and Companion Diagnostics (CDx) by Liquid Biopsy. DIAMOND STUDY Ended
  2024-518017-26-00 Phase II 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• A study to investigate the efficacy and safety of trastuzumab deruxtecan as the first treatment option for locally advanced/metastatic Non-S… Ended
  2023-503674-20-00 Phase III 9 countries AstraZeneca AB
• DESTINY-Breast11 will compare trastuzumab deruxtecan (T-DXd) alone or in sequence with other medications, known as THP, with standard of car… Ended
  2023-505210-18-00 Phase III 4 countries AstraZeneca AB
• Trastuzumab Deruxtecan for Subjects with HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma after Progression on or A… Ended
  2023-507963-20-00 Phase III 10 countries Daiichi Sankyo Inc.
• Study of AZD5305 as Monotherapy and with Anti-Cancer Agents in Patients with Advanced Solid Malignancies Ended
  2022-502856-29-00 Phase I (FiH) 5 countries AstraZeneca AB
• A study to investigate anti-tumor activity and safety of trastuzumab deruxtecan in patients with solid tumors carrying specific HER2 mutatio… Ended
  2024-516158-22-00 Phase II 2 countries AstraZeneca AB
• A study to investigate the efficacy and safety of trastuzumab deruxtecan in patients With or Without Brain Metastasis Who Have Previously-Tr… Ended
  2024-510588-53-00 Phase III/IV 8 countries AstraZeneca AB
• Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive… Ended
  2023-505249-24-00 Phase III 9 countries AstraZeneca AB
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended
  2023-507961-24-00 Phase III 13 countries Daiichi Sankyo Inc.
• DESTINY-Breast07 will investigate the safety, tolerability, and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with o… Ended
  2023-505309-18-00 Phase I/II 4 countries AstraZeneca AB
• The study of Trastuzumab Deruxtecan to assess its efficacy, safety and tolerability in Patients with Selected HER2 Expressing Tumors Ended
  2023-504721-39-02 Phase II 3 countries AstraZeneca AB
• Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Ca… Ended
  2024-516653-44-00 Phase III 12 countries AstraZeneca AB
• Study of Biological Effect in Tumor Samples from Clinical Trial Patients Treated with Ds8201 Ended
  2023-508830-33-00 Phase II 1 country Solti Group
• A Phase IB/II Study to determine efficacy and safety of Durvalumab + Paclitaxel and Durvalumab in Combination with Novel Oncology Therapies … Ended
  2024-511646-40-00 Phase I/II 1 country AstraZeneca AB
• Testing a new targeted therapy trastuzumab deruxtecan (DS-8201a) against ado-trastuzumab emtansine (T-DM1) for patients with advanced stage … Ended
  2024-511204-16-00 Phase III 4 countries Daiichi Sankyo Inc.

Showing 25–48 of 53 trials